These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 12652356

  • 1. The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type II diabetes mellitus.
    Standl E, Füchtenbusch M.
    Diabetologia; 2003 Mar; 46 Suppl 1():M30-6. PubMed ID: 12652356
    [Abstract] [Full Text] [Related]

  • 2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL, Figgitt DP.
    Pharmacoeconomics; 2004 Mar; 22(6):389-411. PubMed ID: 15099124
    [Abstract] [Full Text] [Related]

  • 3. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ, Bailey CJ.
    Drugs; 2005 Mar; 65(3):385-411. PubMed ID: 15669880
    [Abstract] [Full Text] [Related]

  • 4. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
    Campbell IW.
    Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
    [Abstract] [Full Text] [Related]

  • 5. Type II diabetes mellitus.
    Edelman SV.
    Adv Intern Med; 1998 Oct; 43():449-500. PubMed ID: 9506190
    [Abstract] [Full Text] [Related]

  • 6. Rationale and options for combination therapy in the treatment of Type 2 diabetes.
    Van Gaal LF, De Leeuw IH.
    Diabetologia; 2003 Mar; 46 Suppl 1():M44-50. PubMed ID: 12652358
    [Abstract] [Full Text] [Related]

  • 7. [Pharmacological treatment of postprandial hyperglycemia].
    Blickle JF.
    Diabetes Metab; 2000 Jun; 26 Suppl 2():20-4. PubMed ID: 10975046
    [Abstract] [Full Text] [Related]

  • 8. Promising new approaches.
    Reasner CA.
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
    Thomsen RW, Baggesen LM, Søgaard M, Pedersen L, Nørrelund H, Buhl ES, Haase CL, Johnsen SP.
    Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
    [Abstract] [Full Text] [Related]

  • 13. Impact of insulin sensitivity, beta-cell function and glycaemic control on initiation of second-line glucose-lowering treatment in newly diagnosed type 2 diabetes.
    Rathmann W, Strassburger K, Bongaerts B, Bobrov P, Kuss O, Müssig K, Markgraf DF, Szendroedi J, Herder C, Roden M, GDS Group.
    Diabetes Obes Metab; 2017 Jun; 19(6):866-873. PubMed ID: 28127851
    [Abstract] [Full Text] [Related]

  • 14. Gycemic control, mealtime glucose excursions, and diabetic complications in type 2 diabetes mellitus.
    Palumbo PJ.
    Mayo Clin Proc; 2001 Jun; 76(6):609-18. PubMed ID: 11393500
    [Abstract] [Full Text] [Related]

  • 15. The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus.
    Del Prato S, Tiengo A.
    Diabetes Metab Res Rev; 2001 Jun; 17(3):164-74. PubMed ID: 11424229
    [Abstract] [Full Text] [Related]

  • 16. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes.
    Hollingdal M, Sturis J, Gall MA, Damsbo P, Pincus S, Veldhuis JD, Pørksen N, Schmitz O, Juhl CB.
    Diabet Med; 2005 Oct; 22(10):1408-13. PubMed ID: 16176204
    [Abstract] [Full Text] [Related]

  • 17. Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide.
    Owens DR, Cozma LS, Luzio SD.
    Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):19-27. PubMed ID: 12702004
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.
    Johansen OE, Birkeland KI.
    Am J Cardiovasc Drugs; 2007 Dec; 7(5):319-35. PubMed ID: 17953471
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.